ՍելՍեպտ

main_info

  • trade_name:
  • ՍելՍեպտ
  • dosage:
  • 250մգ(100/10x10) բլիստերում
  • pharmaceutical_form:
  • դեղապատիճներ
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • ՍելՍեպտ
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

21-3-2019

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Published on: Wed, 20 Mar 2019 The additive contains viable spores of two strains of Bacillus amyloliquefaciens and a single strain of Bacillus subtilis and is intended to be used with pigs for fattening and minor porcine species at a minimum inclusion level of 1.5 × 108 colony forming units (CFU)/kg complete feedingstuffs. The two bacterial species are considered suitable for the qualified presumption of safety (QPS) approach to safety assessment, which requires the identity of the strains to be establ...

Europe - EFSA - European Food Safety Authority EFSA Journal

2-8-2018

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

"Jian Pai Natural Skin Care Cream" contains antifungal drugs not listed on the label, which may pose serious health risks

Health Canada testing of “Jian Pai Natural Skin Care Cream,” also called ‘’Yikangshuang,” found that it contains two antifungal drugs (fluconazole and miconazole) that are not listed on the product label, and may pose serious health risks.

Health Canada

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

30-7-2018

July 26, 2018: Miami-Dade Resident Charged in Connection with Performance of Illicit Silicone Injections

July 26, 2018: Miami-Dade Resident Charged in Connection with Performance of Illicit Silicone Injections

July 26, 2018: Miami-Dade Resident Charged in Connection with Performance of Illicit Silicone Injections

FDA - U.S. Food and Drug Administration

26-3-2019

Diacerein (Therapicon Srl)

Diacerein (Therapicon Srl)

Diacerein (Active substance: Diacerein) - Refusal of orphan designation - Commission Decision (2019)2360 of Tue, 26 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/131/18

Europe -DG Health and Food Safety

13-3-2019


Loperamide, loperamide / simeticone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010665/201805

Loperamide, loperamide / simeticone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010665/201805

Loperamide, loperamide / simeticone: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010665/201805

Europe - EMA - European Medicines Agency

13-3-2019


Loperamide, loperamide / simeticone: List of nationally authorised medicinal products - PSUSA/00010665/201805

Loperamide, loperamide / simeticone: List of nationally authorised medicinal products - PSUSA/00010665/201805

Loperamide, loperamide / simeticone: List of nationally authorised medicinal products - PSUSA/00010665/201805

Europe - EMA - European Medicines Agency

22-2-2019

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Active substance: voriconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1581 of Fri, 22 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2669/T/21

Europe -DG Health and Food Safety

15-1-2019

EU/3/18/2127 (Therapicon Srl)

EU/3/18/2127 (Therapicon Srl)

EU/3/18/2127 (Active substance: Melatonin) - Orphan designation - Commission Decision (2019)223 of Tue, 15 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001921

Europe -DG Health and Food Safety

13-12-2018

voriconazole

voriconazole

voriconazole (Active substance: voriconazole) - Centralised - Art 28 - (PSUR - Commission Decision (2018)8915 of Thu, 13 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/3127/201802

Europe -DG Health and Food Safety

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type: , therapeutic area: , PIP number: P/0223/2018

Europe - EMA - European Medicines Agency

2-10-2018

Vfend (Pfizer Europe MA EEIG)

Vfend (Pfizer Europe MA EEIG)

Vfend (Active substance: voriconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6490 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/000387/T/0130

Europe -DG Health and Food Safety

25-9-2018

Voriconazole Hikma (Hikma FarmacEutica (Portugal), S.A.)

Voriconazole Hikma (Hikma FarmacEutica (Portugal), S.A.)

Voriconazole Hikma (Active substance: voriconazole) - Centralised - Yearly update - Commission Decision (2018)6286 of Tue, 25 Sep 2018

Europe -DG Health and Food Safety

4-7-2018

Prialt (RIEMSER Pharma GmbH)

Prialt (RIEMSER Pharma GmbH)

Prialt (Active substance: ziconotide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4334 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/551/T/56

Europe -DG Health and Food Safety

24-5-2018

Consultation:  miconazole and fluconazole: proposed advisory statements for medicines

Consultation: miconazole and fluconazole: proposed advisory statements for medicines

The TGA is seeking comments on the proposed RASML statements for OTC medicines containing miconazole or fluconazole. Closing date: 21 June 2018

Therapeutic Goods Administration - Australia